Zelira Therapeutics Ltd. · ASX:ZLD
Zelira Therapeutics — Zelda Therapeutics — Investor Presentation (February 2017)
23 slides from Zelira Therapeutics's investor presentation, Feb 8, 2017
Slide 1: Investor Presentation February 2017
For personal use only Investor Presentation February 2017
Slide 2: Disclaimer and Important Notice
Disclaimer and Important Notice For personal use only Disclaimer This presentation has been prepared by Zelda Therapeutics Ltd ACN 103 782 378 (“Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Co
Slide 3: Corporate Overview
Corporate Overview For personal use only On 22 November 2016 Zelda Therapeutics completed an RTO and debuted on the ASX. The Company raised $4m at 2.5c, issuing a total of 160m new shares. Capital Structure Shares Unrestricted 322,627,649 Management Shares (escrowed 12 months) 122,125,156 36% 37% Sh
Slide 4: Company Overview
Company Overview For personal use only Zelda Therapeutics is a listed California-founded biotechnology company focused on delivering medical cannabis therapies with a strong Australian connection. It was formed to fund clinical efficacy trials of medical cannabis formulations that have been develope
Slide 5: Board & Management Team
Board & Management Team For personal use only Harry Karelis Mara Gordon Jason Peterson Dr Stewart Washer Founder & Executive Founder & Founder & Founder & Chairman Director Director Director Harry is the founder Mara is the co- Jason is a Director, Stewart has 25 years of Titan Capital founder of Au
Slide 6: World-leading Scientific Advisory Board
World-leading Scientific Advisory Board For personal use only Prof. Manuel Guzman Dr Cristina Sanchez Dr Joe Goldstrich Dr Noah Federman Full Professor of Assistant Professor at Distinguished clinical Highly respected Biochemistry and Complutense career in preventive paediatric clinical Molecular Bi
Slide 7: Milestones Achieved Since Listing
Milestones Achieved Since Listing For personal use only Brain Cancer Pancreatic Cancer Partnership in place with the Research collaboration agreement Telethon Kids Institute to focus on signed with Curtin University ASX Listing pre-clinical testing of Aunt Zelda’s to test a range of Aunt Zelda’s Suc
Slide 8: About Medical Cannabis
About Medical Cannabis For personal use only Medical cannabis is fast becoming recognised worldwide as a natural and effective medicine in the treatment of a wide range of ailments and diseases. Medical Regulatory Public perception Compelling clinical evidence Medical cannabis use is currently Perce
Slide 9: Uses of Medical Cannabis
Uses of Medical Cannabis For personal use only A broad range of medical indications have been shown to be alleviated by medical cannabis Cannabis based medication is currently available and used widely to treat the following conditions: • Spasticity in Multiple Sclerosis • Post Traumatic Stress Diso
Slide 10: How Does Medical Cannabis Work?
How Does Medical Cannabis Work? For personal use only Cannabis contains more than 85 types of cannabinoids, the chemical compounds secreted by cannabis flowers Cannabinoid receptors CB1 Different medical effects can and CB2 form part of the be achieved by targeting Endocannabinoid system (ECS) diffe
Slide 11: Currently Targeting Areas in Large Patient Markets
Currently Targeting Areas in Large Patient Markets For personal use only Breast Cancer Brain cancer Insomnia • Over 1.7 million patients in 2012 • 1,600 brain cancers are diagnosed • Affects approximately 35% of the • #1 cancer diagnosed in women. each year in Australia global population Source: Wor
Slide 12: Positive Anti-Cancer Results in Breast Cancer Trials
Positive Anti-Cancer Results in Breast Cancer Trials For personal use only About the Study: • Initial proof of concept study into the anti-cancer effects of its THC-rich medical cannabis formulation • Study compared anti-tumour responses of pure tetrahydrocannabinol (THC) versus the Zelda Therapeuti
Slide 13: Next Steps for Breast Cancer Trials
Next Steps for Breast Cancer Trials For personal use only Positive results provide support to continue the study of Aunt Zelda’s formulations as anti-cancer therapeutics in their own right or in combination with current chemotherapy and radiotherapy regimes Series of follow-on studies are in progres
Slide 14: Strong Partnerships
Strong Partnerships For personal use only Exclusive patient data access Partnership in place with the Collaboration to focus on pre-clinical agreement in place with Aunt Zelda’s prestigious Complutense University testing of Zelda’s compounds, includes formulations & protocols. Madrid for pre-clinica
Slide 15: Competitive Landscape – Where Are We Going?
Competitive Multiple Landscape Therapeutics – Where and Are We Going? Applications For personal use only GW Pharma Existing patient LSE:GWP data Multiple Revenue Canopy indications Growth US$13 million FY16 Multiple TSX:CGC 45 Phase 2/3 formulations clinical trials Revenue CAD$12.7 million FY1
Slide 16: Biotech Company Peer Comparison
Biotech Company Peer Comparison For personal use only Focus Status Share Price Revenue MarketCap Mesoblast (MSB) Chronic heart failure, chronic low back pain and rheumatoid Developed products $1.60 US$0.4m $640m arthritis and diabetic nephropathy and clinical trials (Sept qtr 16) Bionomics (BNO) Can
Slide 17: Key Strategic Benefits Through Partnerships
Key Strategic Benefits Through Partnerships For personal use only 1 Leveraging world class knowledge and expertise in the medical cannabis sector Leading organisations in Australia and the US brings a wealth of expertise Rapid advancement to clinical trails 2 Access to Aunt Zelda’s exclusive patient
Slide 18: Strategy – Cost Effective Path to Market
Strategy – Cost Effective Path to Market For personal use only To develop readily available data packs that form the basis for licensing deals with large pharmaceutical and biotech companies that can continue trials through to market commercialisation. Initially targeting trials Partner with world A
Slide 19: Business Model – Rapid Advancement Towards Licensing Revenue
Business Model – Rapid Advancement Towards Licensing Revenue For personal use only License In Partner & Develop License Out Data Set and Pre-clinical Clinical Studies Further clinical Marketing formulations studies (Efficacy trials) trials as required Licensed from Aunt Partner with CROs to Clinical
Slide 20: Commercialisation and Revenue Model
Commercialisation and Revenue Model 02 For personal use only Commercialisation Conduct studies with License or partner with Design key pre-clinical and clinical research institutions and leading pharma/biotech for studies in-house specialist clinical research phase 3 trials or marketing organisation
Slide 21: Big Pharma Represents a Big Opportunity
Big Pharma Represents a Big Opportunity For personal use only • Top 10 big pharmaceuticals companies globally generated over $380 billion in revenue in 20161 • None of these companies currently have a medical cannabis product or trial in progress • Medical cannabis market represents a huge opportuni
Slide 22: Activity Pipeline and Milestones 2017
Activity Pipeline and Milestones 2017 For personal use only Commencement of Trials and Results • Sleep disorder clinical trials expected to commence in mid 2017 with trial data expected around 6 months later • Pancreatic cancer research programme expected to commence in early 2017 • Breast cancer –
Slide 23: Investment Summary
Investment Multiple Summary and Applications Therapeutics For personal use only Zelda Therapeutics offers investors exposure to a world-class team at very attractive valuations and with significant valuation drivers over the next 12-18 months. Significant market Acceleration straight to Large target
Zelda Therapeutics — Investor Presentation (February 2017) on 6ix